Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,554.00    0.00 (0.00%)
Bid:
2,000.00
Ask:
0.00
Spread: 556.00 (27.80%)
Market Cap: £8.20b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

30 Jun 2022 07:00

RNS Number : 7013Q
Bunzl PLC
30 June 2022
Β 

30 June 2022

Β 

BUNZL PRE-CLOSE STATEMENT

Β 

Bunzl plc, the specialist international distribution and services Group, is updating the market today prior to entering its closed period for the six months ending 30 June 2022.

Β 

The Group is expected to deliver very strong growth over the period, reflecting the resilience and strength of the Bunzl business model. Group revenue in the first half is expected to increase year-on-year by approximately 16% at actual exchange rates and by 12-13% at constant exchange rates1, with inflation continuing to drive underlying revenue growth and the impact of acquisitions further supplementing growth. Group adjusted operating margin for the first half is expected to be slightly higher than historical annual levels.

Β 

Across our business areas inflation remains the key driver of performance. Very strong revenue growth has been maintained in North America over the period and negotiations with our largest customer are constructive and ongoing. Continental Europe similarly maintained strong momentum, whilst the UK & Ireland's operating margin continues to see year-on-year improvement alongside very strong base business recovery. Rest of the World's revenue growth has been moderate, with very strong growth in Asia Pacific partially offset by the expected decline in Covid-19 related sales in Latin America.

Β 

The Group is upgrading its guidance for the year on the basis of very strong revenue growth to date and announced acquisitions. At constant exchange rates the Group now expects very good revenue growth in 2022, driven by good organic revenue growth and the positive contribution of acquisitions announced in the last 12 months. Growth of the base business is expected to be only partially offset by the further normalisation of sales of Covid-19 related products, albeit these are expected to remain ahead of 2019 levels. We continue to expect Group operating margin in 2022 to be slightly higher than historical levels.

Β 

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

Β 

"Bunzl has delivered another period of strong growth. We continue to demonstrate the strength of our business model, supported by the depth and resilience of our supply chains and the agility of our people who have responded to the inflationary environment so successfully. Our acquisition momentum remains strong, with our active pipeline supported by a strong balance sheet."

Β 

Β 

Note:

1. The number of trading days will not have an impact on growth over the period.Β 

Β 

Β 

Enquiries:

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations

Tel: +44 (0)20 7725 5000

Tulchan

Martin Robinson

Olivia Peters

Tel: +44 (0)20 7353 4200

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTBUGDLUSDDGDC
Date   Source Headline
29th Jun 20233:26 pmRNSDirector/PDMR Shareholding
21st Jun 20234:54 pmRNSHolding(s) in Company
15th Jun 20237:00 amRNSTrading Statement
8th Jun 20238:00 amRNSAdditional Listing
5th Jun 202311:00 amRNSDirector/PDMR Shareholding
1st Jun 202311:16 amRNSTotal Voting Rights
30th May 20237:00 amRNSAcquisition
24th May 202312:16 pmRNSHolding(s) in Company
18th May 20238:00 amRNSAdditional Listing
3rd May 20234:15 pmRNSDirector/PDMR Shareholding
2nd May 20234:51 pmRNSDirector/PDMR Shareholding
2nd May 202310:37 amRNSDirector/PDMR Shareholding
2nd May 202310:30 amRNSTotal Voting Rights
2nd May 202310:27 amRNSBlock listing Interim Review
27th Apr 20238:00 amRNSAdditional Listing
26th Apr 20234:34 pmRNSResult of AGM
26th Apr 20237:00 amRNSTrading Statement
20th Apr 20238:00 amRNSAdditional Listing
19th Apr 20235:20 pmRNSHolding(s) in Company
13th Apr 20235:06 pmRNSDirector/PDMR Shareholding
12th Apr 20234:43 pmRNSDirector/PDMR Shareholding
11th Apr 20232:10 pmRNSDirector/PDMR Shareholding
11th Apr 20232:10 pmRNSDirector/PDMR Shareholding
11th Apr 202310:25 amRNSDirector/PDMR Shareholding
11th Apr 202310:17 amRNSDirector/PDMR Shareholding
5th Apr 20234:59 pmRNSDirector/PDMR Shareholding
3rd Apr 202312:30 pmRNSTotal Voting Rights
3rd Apr 202310:30 amRNSDirector/PDMR Shareholding
3rd Apr 20239:35 amRNSDirector/PDMR Shareholding
30th Mar 20238:00 amRNSAdditional Listing
28th Mar 202310:58 amRNSDirector/PDMR Shareholding
28th Mar 20239:21 amRNSDirector/PDMR Shareholding
23rd Mar 20238:00 amRNSAdditional Listing
16th Mar 202312:07 pmRNSAnnual Financial Report
16th Mar 20238:00 amRNSAdditional Listing
3rd Mar 20234:56 pmRNSDirector/PDMR Shareholding
2nd Mar 20233:20 pmRNSDirector/PDMR Shareholding
2nd Mar 202312:13 pmRNSDirector/PDMR Shareholding
2nd Mar 202312:09 pmRNSDirector/PDMR Shareholding
1st Mar 20234:31 pmRNSTotal Voting Rights
1st Mar 20234:02 pmRNSDirector/PDMR Shareholding
27th Feb 20232:00 pmRNSDividend Declaration
27th Feb 20237:00 amRNSFinal Results
27th Feb 20237:00 amRNSAcquisition
7th Feb 20237:00 amRNSDirectorate Change
6th Feb 20232:22 pmRNSDirector/PDMR Shareholding
2nd Feb 20237:00 amRNSCUSTOMER CONTRACT
1st Feb 202310:19 amRNSTotal Voting Rights
10th Jan 20233:44 pmRNSDirector/PDMR Shareholding
6th Jan 20234:07 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.